Evaluation of Matrix Metalloproteinase–9 [MMP] activity in Hypertension

Nelapati Swetha Vinela; M.Vijaya Bhaskar; T.Praveen

Volume : VII, Issue : II, February - 2018

Evaluation of Matrix Metalloproteinase–9 [MMP] activity in Hypertension

Nelapati Swetha Vinela, M. Vijaya Bhaskar, T. Praveen

Abstract :

Hypertension (HTN) can be defined as sustained elevation of systemic arterial pressure above 140/90mm of Hg. It is the level of pressure at which institution of therapy reduces related morbidity and mortality. According to JNC 8 hypertension is classified into primary or essential hypertension and secondary hypertension. Over 90% of patients with high blood pressure have essential Hypertension. Prehypertension is not considered a disease, but identifies those who are likely to progress to stage 1 or stage 2 HTN in the future. Samples were collected from newly diagnosed 200 cases of prehypertension and 200 cases of essential hypertension. 201 cases of Normotensive subjects were recruited from General Medicine Dept. or admitted (IP) under General Medicine Unit of Mamata General Hospital, Khammam. Matrix metalloproteinases are proteolytic enzymes that degrade the extracellular matrix (ECM), the basement memane, and play a role in tissue repair and vascular remodeling. At this point, 23 MMPs have been identified in humans. Increased serum MMP 9 mean values were seen in essential hypertension group (0.162�0.031) when compared with prehypertension (0.183�0.036) and control group (0.250�0.070). The difference between the groups was significant statistically with p–value <0.05.and also found MMp–9 levels were increased as the severity of disease the increased.